Viewing Study NCT00172068


Ignite Creation Date: 2025-12-24 @ 5:56 PM
Ignite Modification Date: 2026-01-26 @ 6:56 PM
Study NCT ID: NCT00172068
Status: TERMINATED
Last Update Posted: 2009-12-23
First Post: 2005-09-13
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
Sponsor: Novartis Pharmaceuticals
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Primary breast cancer View
None Bone metastases View
None Minimal residual disease View
None Bisphosphonates View